核心外素颗粒向膜结合热冲击蛋白70用于癌症治疗
Elena V Svirshchevskaya1, Valentina V Kostenko1, Anna A Boyko1
1Laboratory of Cell Interactions, Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 117997 Moscow, Russia.
Nanomaterials (Basel, Switzerland)
|December 17, 2024
概括
研究人员使用单克隆抗体开发了针对性抗癌纳米颗粒,用于对抗细胞膜暴露的热冲击蛋白70kDa (mHSP70). 这些针对mHSP70的纳米颗粒显示出针对瘤细胞提供抗癌药物的前景.
科学领域:
- 在瘤学瘤学.
- 纳米技术纳米技术
- 免疫学 免疫学 免疫学
背景情况:
- 有针对性的抗癌疗法需要识别瘤特异性分子.
- 细胞膜暴露的热冲击蛋白70 kDa (mHSP70) 在各种癌细胞上过度表达.
研究的目的:
- 分析mHSP70在各种瘤细胞上的表达.
- 为了设计针对mHSP70的基托基纳米颗粒用于药物输送.
主要方法:
- 流式细胞计和共聚焦显微镜评估了mHSP70在2D和3D瘤细胞培养中的表达.
- 酸盐核心纳米粒子 (NP) 与一个模型药物 (合基胺) 结合在一起.
- 针对mHSP70的单克隆抗体 (mAbs) 形成了最终纳米粒子 (CAD-NP) 的外.
主要成果:
- 在乳腺,胰腺,结肠和前列腺癌细胞以及淋巴瘤中检测到mHSP70.
- 鉴定证实了NP的大小,电量和功能.
- 与没有抗体 (CD-NP) 的药物载荷NP相比,CAD-NP对mHSP70阳性瘤细胞具有增强的毒性.
结论:
- 针对mHSP70的单克隆抗体可以在抗瘤治疗中作为有效的向载体.
- mHSP70是开发有针对性的纳米药物输送系统的可行目标.
- 开发的CAD-NP表明了选择性癌症治疗的潜力.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tail-anchoring of Proteins in the ER Membrane
3.1K
Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
3.1K


